KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Short-Term Debt issuances (2017 - 2025)

Boston Scientific (BSX) has disclosed Short-Term Debt issuances for 8 consecutive years, with -$192.0 million as the latest value for Q1 2025.

  • Quarterly Short-Term Debt issuances changed N/A to -$192.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was -$5.0 million through Dec 2025, down 102.67% year-over-year, with the annual reading at -$196.0 million for FY2025, 204.81% down from the prior year.
  • Short-Term Debt issuances hit -$192.0 million in Q1 2025 for Boston Scientific, down from $187.0 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $223.0 million in Q1 2022 to a low of -$192.0 million in Q1 2025.
  • Historically, Short-Term Debt issuances has averaged -$1.1 million across 4 years, with a median of -$20.0 million in 2022.
  • Biggest YoY gain for Short-Term Debt issuances was 153.62% in 2023; the steepest drop was 73.55% in 2023.
  • Year by year, Short-Term Debt issuances stood at $1.0 million in 2022, then plummeted by 4200.0% to -$41.0 million in 2023, then surged by 556.1% to $187.0 million in 2024, then tumbled by 202.67% to -$192.0 million in 2025.
  • Business Quant data shows Short-Term Debt issuances for BSX at -$192.0 million in Q1 2025, $187.0 million in Q4 2024, and -$41.0 million in Q3 2023.